Synthetic biomimetic supra molecular Biovector™ (SMBV™) particles for nasal vaccine delivery

Advanced Drug Delivery Reviews

Volumn 51, Issue 1-3, 2001, Pages 113-125

  Von Hoegen, Paul ^a,b  

^a Biovector Therapeutics   (France)

^b Pharmexa AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; FILTRATION; LIPIDS; POLYSACCHARIDES; PROTEINS; TISSUE; VIRUSES;

CELLULAR IMMUNITY;

VACCINES;

ADJUVANT; BETA GALACTOSIDASE; CD4 ANTIGEN; CD8 ANTIGEN; CHITOSAN; CHOLERA TOXIN; DRUG CARRIER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 2; ISCOM; MEMBRANE PROTEIN; NOSE SPRAY; PEPTIDE; PHOSPHORYL LIPID A; POLYARGININE; POLYSACCHARIDE; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; SUPRA MOLECULAR BIOVECTOR; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; CLINICAL TRIAL; CPG ISLAND; DNA SEQUENCE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; FILTRATION; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; INFLUENZA VACCINES; VACCINES; VACCINES, SYNTHETIC;

EID: 0035940310     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00175-2     Document Type: Review

References (36)

1. Adjuvants for human vaccines - Current status, problems and future prospects
2. Phase I evaluation of intranasal virosomal Influenza vaccine with and without escherichia coli heat-labile toxin in adult volunteers
3. Characterisation and phase behaviour of phospholipide bilayers adsorbed on spherical polysaccharide nanoparticles
4. Structural characterisation (shape and dimensions) and stability of polysaccharide/lipid nanoparticles
5. Structural characterisation of organized systems of polysaccharides and phospholipids by light scattering spectroscopy and electron microscopy
6. Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers
7. The shape, dimension and organisation of maltodextrins gel fragments with and without associated phospholipids
8. A new family of carriers (Biovectors) enhances the immunogenicity of rabies antigens
9. Phase I study of a nasally delivered trivalent Influenza vaccine incorporating inactivated Influenza antigens with supramolecular biovector delivery technology
10. Biovector loaded with a trivalent split Influenza vaccine administered intranasally induce a strong mucosal and serosal immune response in mice
11. Stabilization and enhancement of interleukine-2 in vitro bioactivity by new carriers: Supramolecular Biovectors
12. Humoral and cell-mediated immunity to vero cell-derived Influenza vaccine
13. Nasal residence time evaluation of cationic biovector in human volunteers
14. Screening of cationic compounds as an absorbtion enhancer for nasal drug delivery
15. Chitosan as a novel delivery system for peptide drugs
16. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for Influenza split vaccine
17. N-Trimethyl chitosan chloride as a potential absorbtion enhancer across mucosal surfaces: In vitro evaluation in intestinal epithelial cells (Caco-2)
18. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier
19. Biovector loaded with a trivalent split Influenza vaccine administered intranasally induces a strong mucosal and seric response in mice
20. A novel bioadhesive intranasal system for inactivated Influenza vaccines
21. Combination of human cytomegalovirus recombinant immediate-early protein (IEI) with 80 nm cationic Biovectors: Protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro
22. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant
23. Comparison of the clearance of radiolabbelled nose drops and nasal spray as mucosally delivered vaccine
24. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: Studies on the effect of vehicle volume
25. Intranasal immunization against Influenza virus using polymeric particles
26. Nasal-associated lymphoid tissue: Phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site
27. Heterosubtypic immunity to Influenza A infection requires B cells but not CD8+ cytotoxic T lymphocytes
28. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity
29. IgA immunodeficiency leads to inadequate T cell priming and increased susceptibility to Influenza virus infection
30. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins
31. Gene tag: Just a way to follow tumor cells or induction of new antigens?
32. Pattern and load of spontaneous metastasis dependent on host immune status studied with a lacZ transduced lymphoma
33. Comparison of in vitro immunostimulatory potential of live and inactivated Influenza virus
34. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
35. Introduction of the haemagglutinin transmembrane region in the Influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8 (+) cytotoxic T lymphocytes
36. Improved oligonucleotide uptake and stability by a new drug carrier, the supramolecular biovector (SMBV)